SG11201900895QA - Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy - Google Patents
Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopyInfo
- Publication number
- SG11201900895QA SG11201900895QA SG11201900895QA SG11201900895QA SG11201900895QA SG 11201900895Q A SG11201900895Q A SG 11201900895QA SG 11201900895Q A SG11201900895Q A SG 11201900895QA SG 11201900895Q A SG11201900895Q A SG 11201900895QA SG 11201900895Q A SG11201900895Q A SG 11201900895QA
- Authority
- SG
- Singapore
- Prior art keywords
- self
- international
- protein
- assay
- michael
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 238000003556 assay Methods 0.000 title abstract 4
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- 238000004611 spectroscopical analysis Methods 0.000 title abstract 3
- 230000001419 dependent effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 1
- 235000020061 kirsch Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N2021/258—Surface plasmon spectroscopy, e.g. micro- or nanoparticles in suspension
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376788P | 2016-08-18 | 2016-08-18 | |
| PCT/US2017/047630 WO2018035470A1 (en) | 2016-08-18 | 2017-08-18 | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900895QA true SG11201900895QA (en) | 2019-02-27 |
Family
ID=59746357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900895QA SG11201900895QA (en) | 2016-08-18 | 2017-08-18 | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11428695B2 (ko) |
| EP (2) | EP3761035B1 (ko) |
| JP (3) | JP6959327B2 (ko) |
| KR (3) | KR20230074614A (ko) |
| CN (2) | CN115468919A (ko) |
| AU (2) | AU2017313150B2 (ko) |
| BR (1) | BR112019003175A2 (ko) |
| CA (1) | CA3032361A1 (ko) |
| DK (2) | DK3761035T3 (ko) |
| EA (1) | EA201990316A1 (ko) |
| ES (1) | ES2837093T3 (ko) |
| FI (1) | FI3761035T3 (ko) |
| HU (1) | HUE052805T2 (ko) |
| IL (2) | IL307435A (ko) |
| MX (1) | MX2019001930A (ko) |
| PL (1) | PL3500856T3 (ko) |
| SG (1) | SG11201900895QA (ko) |
| WO (1) | WO2018035470A1 (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3761035B1 (en) | 2016-08-18 | 2024-02-14 | Regeneron Pharmaceuticals, Inc. | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy |
| JOP20200275A1 (ar) | 2018-05-10 | 2020-11-02 | Regeneron Pharma | صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز |
| CN113588582B (zh) * | 2020-04-30 | 2024-05-14 | 上海药明生物技术有限公司 | 蛋白质样品浓度测定方式选择法及测定方法 |
| WO2023095154A1 (en) * | 2021-11-24 | 2023-06-01 | Sensoville Biotech Pvt Ltd | Method for determining changes in a protein's structure |
| WO2023141319A1 (en) * | 2022-01-24 | 2023-07-27 | Amgen Inc. | Methods for detecting antibody self-association |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US771997A (en) | 1903-11-21 | 1904-10-11 | Alfred Palm | Lathe attachment. |
| US4254102A (en) * | 1975-09-08 | 1981-03-03 | Plough, Inc. | Substantive PABA compositions |
| US4080264A (en) | 1976-03-01 | 1978-03-21 | Massachusetts Institute Of Technology | Immunoassay by light scattering spectroscopy |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7514938B2 (en) | 2004-05-11 | 2009-04-07 | Board Of Regents Of The University And College System Of Nevada, On Behalf Of The University Of Nevada, Reno | Dielectric relaxation spectroscopy apparatus and methods of use |
| TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| WO2007121363A2 (en) | 2006-04-13 | 2007-10-25 | Mississippi State University | An optical apparatus for simultaneously measuring the scattering and concentration signals of macromolecules in a flow cell |
| CN101522219A (zh) | 2006-10-12 | 2009-09-02 | 惠氏公司 | 改变抗体溶液中离子强度以减少乳光/聚集物 |
| PL2150617T3 (pl) | 2007-06-04 | 2015-04-30 | Regeneron Pharma | Wzmocniona ekspresja i regiony stabilności |
| EP2200932A4 (en) * | 2007-09-21 | 2014-09-10 | Cytimmune Sciences Inc | NANOTHERAPEUTIC COLLOIDAL METAL COMPOSITIONS AND METHODS |
| US20110305765A1 (en) | 2008-11-21 | 2011-12-15 | Board Of Regents, The University Of Texas System | Preparation and methodology of silk fibroin nanoparticles |
| WO2014192937A1 (ja) * | 2013-05-30 | 2014-12-04 | 公立大学法人大阪府立大学 | 被検出物質の検出装置および方法 |
| WO2015038811A2 (en) * | 2013-09-11 | 2015-03-19 | Arsia Therapeutics, Inc. | Liquid protein formulations containing ionic liquids |
| WO2015196091A1 (en) * | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| CN104062287B (zh) | 2014-07-01 | 2017-08-08 | 福建工程学院 | 一种基于纳米金催化的化学发光分析检测铁蛋白的方法 |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| WO2016115475A1 (en) * | 2015-01-18 | 2016-07-21 | Biogen Ma Inc. | Anti-cd40 antibody formulations |
| EP3761035B1 (en) | 2016-08-18 | 2024-02-14 | Regeneron Pharmaceuticals, Inc. | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy |
-
2017
- 2017-08-18 EP EP20191942.0A patent/EP3761035B1/en active Active
- 2017-08-18 BR BR112019003175A patent/BR112019003175A2/pt unknown
- 2017-08-18 KR KR1020237016537A patent/KR20230074614A/ko not_active Application Discontinuation
- 2017-08-18 CA CA3032361A patent/CA3032361A1/en active Pending
- 2017-08-18 PL PL17761159T patent/PL3500856T3/pl unknown
- 2017-08-18 WO PCT/US2017/047630 patent/WO2018035470A1/en unknown
- 2017-08-18 CN CN202211108451.8A patent/CN115468919A/zh active Pending
- 2017-08-18 EA EA201990316A patent/EA201990316A1/ru unknown
- 2017-08-18 ES ES17761159T patent/ES2837093T3/es active Active
- 2017-08-18 JP JP2019508809A patent/JP6959327B2/ja active Active
- 2017-08-18 DK DK20191942.0T patent/DK3761035T3/da active
- 2017-08-18 US US16/326,238 patent/US11428695B2/en active Active
- 2017-08-18 IL IL307435A patent/IL307435A/en unknown
- 2017-08-18 KR KR1020227030436A patent/KR102534506B1/ko active IP Right Grant
- 2017-08-18 CN CN201780050825.6A patent/CN109661577B/zh active Active
- 2017-08-18 FI FIEP20191942.0T patent/FI3761035T3/fi active
- 2017-08-18 SG SG11201900895QA patent/SG11201900895QA/en unknown
- 2017-08-18 DK DK17761159.7T patent/DK3500856T3/da active
- 2017-08-18 MX MX2019001930A patent/MX2019001930A/es unknown
- 2017-08-18 IL IL264640A patent/IL264640B2/en unknown
- 2017-08-18 AU AU2017313150A patent/AU2017313150B2/en active Active
- 2017-08-18 HU HUE17761159A patent/HUE052805T2/hu unknown
- 2017-08-18 KR KR1020197006376A patent/KR102441221B1/ko active IP Right Grant
- 2017-08-18 EP EP17761159.7A patent/EP3500856B1/en active Active
-
2021
- 2021-10-07 JP JP2021165510A patent/JP7321227B2/ja active Active
-
2022
- 2022-07-20 US US17/868,983 patent/US11988668B2/en active Active
-
2023
- 2023-07-25 JP JP2023120438A patent/JP2023139189A/ja active Pending
- 2023-12-04 AU AU2023274236A patent/AU2023274236A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900895QA (en) | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201903674YA (en) | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201903889TA (en) | Crenolanib for treating flt3 mutated proliferative disorders associated mutations | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
| SG11201908650PA (en) | Optimized antibody compositions for treatment of ocular disorders | |
| SG11201906301UA (en) | Methods of manufacture of nut flours and formulations for oral immunotherapy | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201908092RA (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists |